Transparency Trials: EU's Vaccine Contract Controversy

An adviser to Europe's top court recommended dismissing the European Commission's appeal against a ruling that mandates the disclosure of information on COVID-19 vaccine contracts. The Commission's handling of contract transparency has been criticized, including issues related to privacy and commercial interests.

An adviser to the European Union's apex court stated that the appeal filed by the European Commission against a 2024 ruling should be rejected. The original ruling required the Commission to reveal specifics of its COVID-19 vaccine contracts.

During the pandemic, the Commission negotiated substantial contracts with pharmaceutical giants like Pfizer and BioNTech for its 27 member states. Despite these efforts, the disclosed contracts had several redactions, guarding individuals’ privacy and commercial interests. The European Commission's appeal challenges the General Court’s decision to favor transparency.

Advocate General Athanasios Rantos commented that the General Court rightly identified transparency in COVID-19 vaccine negotiations as a public interest within EU law. His remarks, although advisory, suggest a setback for the Commission, stirring debates on the EU's transparency under President Ursula von der Leyen's administration.